Neogenomics INC 8-K filings

NeoGenomics, Inc. announced the departure of its EVP, General Counsel & Business Development, Alicia Olivo, effective September 21, 2026.

NeoGenomics announced second-quarter 2026 results with an 11% year-over-year revenue increase to $202 million, driven by robust clinical services and NGS growth, leading to raised full-year guidance.

NeoGenomics has finalized a civil settlement with the U.S. Department of Justice, agreeing to pay $9,813,260 to resolve an investigation into consulting services provided to healthcare providers.

NeoGenomics has finalized a civil settlement with the Department of Justice, agreeing to pay $9,813,260 to resolve an investigation into consulting services provided to healthcare providers.

NeoGenomics has expanded its Board of Directors to ten members with the appointment of former Flatiron Health CEO Carolyn Starrett.

NeoGenomics announced the pricing of a $275 million offering of convertible senior notes due 2032 to qualified institutional buyers, alongside a concurrent repurchase of existing notes.

NeoGenomics has initiated a private offering of $275 million in convertible senior notes due 2032 to fund debt repurchases and share buybacks.

NeoGenomics stockholders approved the election of nine directors and an increase of 5 million shares for the 2023 Equity Incentive Plan.

NeoGenomics reported record first-quarter revenue of $187 million, an 11% year-over-year increase, and raised its full-year 2026 revenue guidance.

NeoGenomics, Inc. announced double-digit revenue growth for Q4 and full year 2025, alongside the imminent clinical launch of its RaDaR ST MRD assay and positive 2026 financial guidance.

NeoGenomics announced preliminary unaudited fourth quarter and full-year 2025 revenue growth and a planned Chief Financial Officer succession.

NeoGenomics, Inc. announced the appointment of John P. 'Jack' Kenny, a seasoned diagnostics and lab services industry veteran, to its Board of Directors, filling the vacancy left by Dr. Alison L. Hannah.

NeoGenomics, Inc. reported a 12% year-over-year increase in third-quarter 2025 consolidated revenue to $188 million, driven by strong clinical and NGS revenue growth, while reaffirming its full-year financial guidance.

Elizabeth Floegel has resigned from the Board of Directors of NeoGenomics, Inc., effective immediately, with no reported disagreements.

NeoGenomics, Inc. announced a 10% increase in second-quarter 2025 consolidated revenue to $181 million, alongside a 142% rise in net loss to $45 million, leading to a revised full-year 2025 financial guidance.

NeoGenomics, Inc. has expanded its Board of Directors to ten members with the appointment of Dr. Marjorie Green, a seasoned oncology executive from Merck, effective June 19, 2025.

NeoGenomics, Inc. announced that its stockholders approved all five proposals at the Annual Meeting, including an amendment to the 2023 Equity Incentive Plan and the advisory vote on executive compensation.

NeoGenomics announced an 8% increase in consolidated revenue to $168 million and a 102% increase in adjusted EBITDA to $7 million for the first quarter of 2025.

NeoGenomics updates its bylaws to establish new advance notice procedures and disclosure requirements for stockholder director nominations, effective April 4, 2025.

NeoGenomics, Inc. has entered into an employment agreement with Anthony Zook, appointing him as Chief Executive Officer, effective April 1, 2025, detailing his compensation, benefits, and severance terms.

NeoGenomics promotes Warren Stone to President & COO, expanding his responsibilities, while Melody Harris departs as Chief Operations Officer.

NeoGenomics promotes Warren Stone to President & COO, expanding his responsibilities to include lab operations and data solutions, while eliminating the Chief Operations Officer role.

NeoGenomics announces a 12% increase in full-year revenue to $661 million, marking the ninth consecutive quarter of double-digit revenue growth.

NeoGenomics projects 12-13% annual revenue growth and provides 2025 financial guidance with revenue between $735 million and $745 million and adjusted EBITDA between $55 million and $58 million.

NeoGenomics, Inc. announced the retirement of CEO Chris Smith effective April 1, 2025, and the appointment of Tony Zook as the new CEO.

NeoGenomics announced a 10% increase in consolidated revenue and a 305% increase in adjusted EBITDA for the third quarter of 2024, leading to an improved full-year outlook.

NeoGenomics announced a 12% increase in second-quarter revenue to $165 million, driven by a 15% rise in Clinical Services revenue, and raised its full-year revenue and adjusted EBITDA guidance.

NeoGenomics held its annual meeting on May 23, 2024, where stockholders elected nine directors, approved executive compensation on an advisory basis, approved an amendment to the Employee Stock Purchase Plan, and ratified the appointment of Deloitte & Touche LLP as the independent auditor.

NeoGenomics announced a 14% increase in first-quarter 2024 revenue to $156 million, driven by a 17% rise in Clinical Services revenue.

NeoGenomics has announced a restructuring that includes the elimination of the President of Advanced Diagnostics role and changes to other executive positions.